{"id":{"repo_id":"glasgow","oai_identifier":"oai:theses.gla.ac.uk:2629"},"canonical_url":"https://search.ndltd.org/etd/glasgow/oai:theses.gla.ac.uk:2629","repository":{"repo_id":"glasgow","name":"University of Glasgow","base_url":"https://theses.gla.ac.uk/cgi/oai2"},"display":{"title":"The role of the cytokines IL-17A and IL-33 in inflammatory arthritis and psoriasis","abstract":"The inflammatory autoimmune diseases rheumatoid arthritis, psoriatic arthritis and psoriasis have seen a break through in therapy by targeting cytokines in the last decade. Interleukin-17A, a potential new target, is considered as a crucial player in rheumatoid arthritis, and has been suggested to be produced by CD4+ T cells (Th17 cells). I explored the cellular sources of IL-17A in human established RA synovium. Surprisingly, only a small proportion of IL-17 positive cells were T cells without expression of a Th17 marker CCR6. Unexpectedly, the majority of IL-17A expression colocalized within mast cells. These data do not contradict a crucial role for IL-17A in RA pathogenesis, however, suggest that in addition to Th17 cells, cells of the innate immune system, particularly mast cells, may be an important component of the effector IL-17A response. Psoriasis is a common chronic autoimmune disease of the skin characterized by hyperplasia of epidermal keratinocytes with associated inflammation. IL-33 is a new member of the IL-1 superfamily that signals through the ST2 receptor and was originally defined as an inducer of T helper 2 (Th2) cytokines. Recently broader immune potential has been discovered for IL-33 particularly via mast cell activation. With its expression at body barrier surfaces it is assumed to act as an alarmin. In this thesis I demonstrate that IL-33 expression is up regulated in the epidermis of psoriatic lesions, compared to healthy skin, thus indicating that IL-33 may be a mediator regulating crosstalk between keratinocytes and infiltrating immune cells in psoriatic plaques. In a phorbol ester-induced model of skin inflammation ST2-/- mice exhibited reduced cutaneous inflammatory responses compared to WT mice. Furthermore, consecutive injections of IL-33 into the ears of mice induced a psoriasis-like inflammatory lesion. This was partially mast cell dependent and cellular analysis demonstrated recruitment of neutrophils to the ear. This concludes that IL-33, via activation of mast cells and recruitment of neutrophils, may play a role in psoriasis plaque inflammation. In the last part of the thesis I tested if nanoparticles can be utilized to image cytokine driven inflammation. Bio-linkages with protein-nanoparticles have been established and in vivo detection of nanoparticles performed. This final interdisciplinary outlook demonstrates a still to be established/finalized method with great potential.","abstract_html":"The inflammatory autoimmune diseases rheumatoid arthritis, psoriatic arthritis and psoriasis have seen a break through in therapy by targeting cytokines in the last decade. Interleukin-17A, a potential new target, is considered as a crucial player in rheumatoid arthritis, and has been suggested to be produced by CD4+ T cells (Th17 cells). I explored the cellular sources of IL-17A in human established RA synovium. Surprisingly, only a small proportion of IL-17 positive cells were T cells without expression of a Th17 marker CCR6. Unexpectedly, the majority of IL-17A expression colocalized within mast cells. These data do not contradict a crucial role for IL-17A in RA pathogenesis, however, suggest that in addition to Th17 cells, cells of the innate immune system, particularly mast cells, may be an important component of the effector IL-17A response. Psoriasis is a common chronic autoimmune disease of the skin characterized by hyperplasia of epidermal keratinocytes with associated inflammation. IL-33 is a new member of the IL-1 superfamily that signals through the ST2 receptor and was originally defined as an inducer of T helper 2 (Th2) cytokines. Recently broader immune potential has been discovered for IL-33 particularly via mast cell activation. With its expression at body barrier surfaces it is assumed to act as an alarmin. In this thesis I demonstrate that IL-33 expression is up regulated in the epidermis of psoriatic lesions, compared to healthy skin, thus indicating that IL-33 may be a mediator regulating crosstalk between keratinocytes and infiltrating immune cells in psoriatic plaques. In a phorbol ester-induced model of skin inflammation ST2-/- mice exhibited reduced cutaneous inflammatory responses compared to WT mice. Furthermore, consecutive injections of IL-33 into the ears of mice induced a psoriasis-like inflammatory lesion. This was partially mast cell dependent and cellular analysis demonstrated recruitment of neutrophils to the ear. This concludes that IL-33, via activation of mast cells and recruitment of neutrophils, may play a role in psoriasis plaque inflammation. In the last part of the thesis I tested if nanoparticles can be utilized to image cytokine driven inflammation. Bio-linkages with protein-nanoparticles have been established and in vivo detection of nanoparticles performed. This final interdisciplinary outlook demonstrates a still to be established/finalized method with great potential.","abstract_has_math":false,"creators":["Hueber, Axel Johannes"],"institution":"University of Glasgow","degree_name":null,"degree_level":"PhD","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011","date_published":"2011","updated_at":"2026-11-19T08:20:43Z","subjects":["QH301 Biology"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/10.5525/gla.thesis.2629","outbound_label":"DOI","outbound_source":"dc:identifier.doi","record_url":"https://doi.org/10.5525/gla.thesis.2629","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier.doi","download_url":"https://theses.gla.ac.uk/2629/1/2011hueberphd.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://theses.gla.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Atheses.gla.ac.uk%3A2629","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Hueber, Axel Johannes"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2011"]},{"key":"dc:date.issued","label":"Date","values":["2011"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Glasgow"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://theses.gla.ac.uk/2629/"]},{"key":"dc:relation.isreferencedby.uri","label":"Dc Relation Isreferencedby URI","values":["https://gla.on.worldcat.org/oclc/742943142"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["PhD"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QH301 Biology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.doi","label":"DOI","values":["10.5525/gla.thesis.2629"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://theses.gla.ac.uk/2629/1/2011hueberphd.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The inflammatory autoimmune diseases rheumatoid arthritis, psoriatic arthritis and psoriasis have seen a break through in therapy by targeting cytokines in the last decade. Interleukin-17A, a potential new target, is considered as a crucial player in rheumatoid arthritis, and has been suggested to be produced by CD4+ T cells (Th17 cells). I explored the cellular sources of IL-17A in human established RA synovium. Surprisingly, only a small proportion of IL-17 positive cells were T cells without expression of a Th17 marker CCR6. Unexpectedly, the majority of IL-17A expression colocalized within mast cells. These data do not contradict a crucial role for IL-17A in RA pathogenesis, however, suggest that in addition to Th17 cells, cells of the innate immune system, particularly mast cells, may be an important component of the effector IL-17A response. Psoriasis is a common chronic autoimmune disease of the skin characterized by hyperplasia of epidermal keratinocytes with associated inflammation. IL-33 is a new member of the IL-1 superfamily that signals through the ST2 receptor and was originally defined as an inducer of T helper 2 (Th2) cytokines. Recently broader immune potential has been discovered for IL-33 particularly via mast cell activation. With its expression at body barrier surfaces it is assumed to act as an alarmin. In this thesis I demonstrate that IL-33 expression is up regulated in the epidermis of psoriatic lesions, compared to healthy skin, thus indicating that IL-33 may be a mediator regulating crosstalk between keratinocytes and infiltrating immune cells in psoriatic plaques. In a phorbol ester-induced model of skin inflammation ST2-/- mice exhibited reduced cutaneous inflammatory responses compared to WT mice. Furthermore, consecutive injections of IL-33 into the ears of mice induced a psoriasis-like inflammatory lesion. This was partially mast cell dependent and cellular analysis demonstrated recruitment of neutrophils to the ear. This concludes that IL-33, via activation of mast cells and recruitment of neutrophils, may play a role in psoriasis plaque inflammation. In the last part of the thesis I tested if nanoparticles can be utilized to image cytokine driven inflammation. Bio-linkages with protein-nanoparticles have been established and in vivo detection of nanoparticles performed. This final interdisciplinary outlook demonstrates a still to be established/finalized method with great potential."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["The role of the cytokines IL-17A and IL-33 in inflammatory arthritis and psoriasis"]}]}],"canonical_facts":{"dc:creator":["Hueber, Axel Johannes"],"dc:date":["2011"],"dc:date.issued":["2011"],"dc:description.abstract":["The inflammatory autoimmune diseases rheumatoid arthritis, psoriatic arthritis and psoriasis have seen a break through in therapy by targeting cytokines in the last decade. Interleukin-17A, a potential new target, is considered as a crucial player in rheumatoid arthritis, and has been suggested to be produced by CD4+ T cells (Th17 cells). I explored the cellular sources of IL-17A in human established RA synovium. Surprisingly, only a small proportion of IL-17 positive cells were T cells without expression of a Th17 marker CCR6. Unexpectedly, the majority of IL-17A expression colocalized within mast cells. These data do not contradict a crucial role for IL-17A in RA pathogenesis, however, suggest that in addition to Th17 cells, cells of the innate immune system, particularly mast cells, may be an important component of the effector IL-17A response. Psoriasis is a common chronic autoimmune disease of the skin characterized by hyperplasia of epidermal keratinocytes with associated inflammation. IL-33 is a new member of the IL-1 superfamily that signals through the ST2 receptor and was originally defined as an inducer of T helper 2 (Th2) cytokines. Recently broader immune potential has been discovered for IL-33 particularly via mast cell activation. With its expression at body barrier surfaces it is assumed to act as an alarmin. In this thesis I demonstrate that IL-33 expression is up regulated in the epidermis of psoriatic lesions, compared to healthy skin, thus indicating that IL-33 may be a mediator regulating crosstalk between keratinocytes and infiltrating immune cells in psoriatic plaques. In a phorbol ester-induced model of skin inflammation ST2-/- mice exhibited reduced cutaneous inflammatory responses compared to WT mice. Furthermore, consecutive injections of IL-33 into the ears of mice induced a psoriasis-like inflammatory lesion. This was partially mast cell dependent and cellular analysis demonstrated recruitment of neutrophils to the ear. This concludes that IL-33, via activation of mast cells and recruitment of neutrophils, may play a role in psoriasis plaque inflammation. In the last part of the thesis I tested if nanoparticles can be utilized to image cytokine driven inflammation. Bio-linkages with protein-nanoparticles have been established and in vivo detection of nanoparticles performed. This final interdisciplinary outlook demonstrates a still to be established/finalized method with great potential."],"dc:format":["application/pdf"],"dc:identifier.doi":["10.5525/gla.thesis.2629"],"dc:identifier.uri":["https://theses.gla.ac.uk/2629/1/2011hueberphd.pdf"],"dc:language":["en"],"dc:publisher.institution":["University of Glasgow"],"dc:relation.isreferencedby":["https://theses.gla.ac.uk/2629/"],"dc:relation.isreferencedby.uri":["https://gla.on.worldcat.org/oclc/742943142"],"dc:subject":["QH301 Biology"],"dcterms:accessrights":["public"],"dc:title":["The role of the cytokines IL-17A and IL-33 in inflammatory arthritis and psoriasis"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["PhD"]},"updated_at":"2026-11-19T08:20:43Z"}